CriticalAntiviral for systemic use, HIV-1 protease inhibitor; used only with a pharmacokinetic booster (ritonavir or cobicistat)×Atypical antipsychotics
Updated · Methodology
Mechanism
The liver metabolises quetiapine mainly through CYP3A4, and its metabolite norquetiapine is also formed and cleared through this enzyme (quetiapine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Darunavir is taken only with a booster (ritonavir or cobicistat), and the boosted regimen inhibits CYP3A (darunavir SmPC, European Medicines Agency, EMA). The pair has not been studied, but quetiapine levels will probably rise (darunavir SmPCs, AEMPS and EMA). For comparison, ketoconazole, another CYP3A4 inhibitor, increased the quetiapine area under the curve (AUC) 5- to 8-fold (quetiapine SmPC, AEMPS). High quetiapine levels can increase its toxicity and lead to coma (darunavir SmPC, AEMPS).
Symptoms
The main danger of the pair is a rise in quetiapine levels that can lead to coma (darunavir and ritonavir summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, and European Medicines Agency, EMA). At high levels, the known effects of quetiapine become stronger: drowsiness and sedation, fast heartbeat and anticholinergic effects such as urinary retention. Blood pressure may fall, including on standing, with dizziness and a risk of falls, especially in older people (quetiapine SmPC, AEMPS). Very high levels, as in overdose, can cause QT prolongation, seizures, muscle breakdown (rhabdomyolysis), respiratory depression, confusion, delirium, agitation, coma and death (quetiapine SmPC, AEMPS).
Management
The combination is contraindicated. Quetiapine is on the contraindication list of darunavir boosted with either ritonavir or cobicistat, including the fixed-dose darunavir/cobicistat tablet (darunavir and darunavir/cobicistat summaries of product characteristics, SmPCs, European Medicines Agency, EMA, and Spanish Agency of Medicines and Medical Devices, AEMPS). Quetiapine itself is contraindicated with CYP3A4 inhibitors, and its SmPC names human immunodeficiency virus (HIV) protease inhibitors among them (quetiapine SmPC, AEMPS). When ritonavir is the booster, the ritonavir SmPC also contraindicates quetiapine (ritonavir SmPC, EMA). The US darunavir labels are less strict. If a patient already taking quetiapine starts darunavir, consider another HIV regimen. If the combination is necessary, reduce the quetiapine dose to one sixth of the current dose and monitor for quetiapine adverse reactions (darunavir and darunavir/cobicistat labels, US Food and Drug Administration, FDA). Under the US quetiapine label, reduce the quetiapine dose to one sixth of the original while the patient takes a strong CYP3A4 inhibitor. When the inhibitor is stopped, increase the dose 6-fold (quetiapine FDA label). Quetiapine has no specific antidote. In severe poisoning, secure the airway and breathing and monitor and support the cardiovascular system. Treat resistant hypotension with intravenous fluids or sympathomimetics, but not with epinephrine or dopamine (quetiapine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica: Ritonavir (EU/1/96/016), sección 4.3 (2026)– EMA, Norvir, ficha técnica en CIMA (nº registro 96016005), consultada 03.10.2026, secciones 4.3, 4.4 y 4.5
- FDA: Seroquel (quetiapine) prescribing information (2026)– FDA label, H2-Pharma, LLC, DailyMed setid 8ae62aaf-f8c5-417f-baac-0098369ca322, revised 04/2026, section 7
- FDA: Prezista (darunavir) prescribing information (2025)– FDA, DailyMed, setid 814301f9-c990-46a5-b481-2879a521a16f, SPL 08/2025 (Revised 03/2023), sections 4 and 7 (Table 10)
- EMA: Ficha técnica: Darunavir (Prezista, EU/1/06/380), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 106380007 (EU/1/06/380), secciones 4.3 y 4.5, consultado 10/2026
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.5 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Quetiapina (nº registro 63054), sección 4.3 (2024)– AEMPS, CIMA, nº registro 63054 (Seroquel 25 mg comprimidos recubiertos con película, Cheplapharm), revisión 12/2024, secciones 4.3, 4.4, 4.5, 4.8 y 4.9
- AEMPS: Ficha técnica: Darunavir (Darunavir Aurovitas, nº registro 84835), sección 4.5 (2023)– AEMPS, CIMA, nº registro 84835, revisión 09/2023, secciones 4.3 y 4.5
- FDA: PREZCOBIX (darunavir and cobicistat) prescribing information (2026)– FDA, DailyMed setid 9c38fdb6-d0ba-4f16-a0e3-85d9ec334d9f (Janssen Products), revisión 02/2026 (versión 29), secciones 4, 6.2, 7.1 y 7.3